Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clobetasol propionate + tazarotene is a topical combination drug used primarily for the treatment of plaque psoriasis. Clobetasol propionate is a super-potent synthetic corticosteroid that acts by reducing inflammation, itching, and swelling through vasoconstriction and suppression of immune responses in the skin. Tazarotene is a third-generation retinoid (vitamin A derivative) that normalizes keratinocyte differentiation, reduces hyperproliferation, and exerts anti-inflammatory effects by modulating gene expression via retinoic acid receptors. The combination leverages the rapid anti-inflammatory action of clobetasol with the disease-modifying effects of tazarotene to improve efficacy and reduce side effects such as steroid-induced skin atrophy when compared to monotherapy. This fixed-dose combination has been shown to be effective in clinical studies for moderate-to-severe plaque psoriasis[4][9]. It is typically formulated as an ointment or lotion for topical application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + tazarotene.